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Background: Infection in young infants is a major cause of morbidity and 
mortality in low-middle income countries, with high neonatal mortality 
rates. timely case management is lifesaving, but the current standard of 
hospitalization for parenteral antibiotic therapy is not always feasible. Alter-
native, simpler antibiotic regimens that could be used in outpatient settings 
have the potential to save thousands of lives.
Methods: this trial aims to determine whether 2 simplified antibiotic 
regimens are equivalent to the reference therapy with 7 days of once-
daily (OD) intramuscular (Im) procaine penicillin and gentamicin for 
outpatient management of young infants with clinically presumed sys-
temic bacterial infection treated in primary health-care clinics in 5 com-
munities in Karachi, pakistan. the reference regimen is close to the cur-
rent recommendation of the hospital-based intravenous ampicillin and 
gentamicin therapy for neonatal sepsis. the 2 comparison arms are (1) 
Im gentamicin OD and oral amoxicillin twice daily for 7 days; and (2) 
Im penicillin and gentamicin OD for 2 days, followed by oral amoxicil-
lin twice daily for 5 days; 2250 “evaluable” infants will be enrolled. the 
primary outcome of this trial is treatment failure (death, deterioration or 
lack of improvement) within 7 days of enrollment. Results are expected 
by early 2014.
Discussion: this trial will determine whether simplified antibiotic regimens 
with fewer injections in combination with high-dose amoxicillin are equiva-
lent to 7 days of Im procaine penicillin and gentamicin in young infants 
with clinical severe infection. Results will have program and policy impli-
cations in countries with limited access to hospital care and high burden of 
neonatal deaths.
Key Words: newborn, neonatal, infant, sepsis, infection, case management, 
community, clinic, outpatient, pakistan
(Pediatr Infect Dis J 2013;32:S19–S25)
Infection in the young infant (0–59 days) is a major cause of mor-bidity and mortality in low-middle income countries, with high 
neonatal mortality rates.1,2 the World Health Organization (WHO) 
estimates that globally, approximately 40% of all child deaths are 
in the neonatal (0–27 day) period and a third are attributable to 
serious bacterial infections.2 timely case management could save 
thousands of lives, and thus is an important strategy for improving 
child survival and meeting un millennium Development Goal 4 
targets for reduction of child mortality in developing countries.
most neonatal deaths in developing countries occur at home, 
with few coming to formal medical attention.1,3 moreover, sick 
newborns who are hospitalized experience very high case fatality 
rates (20–40%), most commonly from multidrug-resistant hospital-
acquired infections related to inadequate infection control standards 
in newborn nurseries in developing countries, as well as due to delays 
in care-seeking.4 WHO recommends hospitalization and 10 or more 
days of parenteral therapy with penicillin/ampicillin and gentamicin 
for neonates with sepsis.5 this recommendation is often difficult to 
put in practice as most families are unable or unwilling to use such 
care for a variety of sociocultural and economic reasons.6 thus, there 
is a strong rationale for the development of simple management and 
referral guidelines for common life-threatening infections that can be 
applied in community and first-level facility settings and scaled up 
for use by national maternal and child health programs.
In his pioneering work, Dr. Abhay Bang in Gadchiroli, India, 
demonstrated a 76% reduction in sepsis-specific neonatal mortality 
through home-based neonatal care and infection management.7 Baqui 
et al8 recently showed the effectiveness of a community-based pack-
age of newborn health interventions in rural Bangladesh, including 
home-based diagnosis and treatment of infection with a 7- to 10-day 
course of intramuscular (Im) penicillin and gentamicin if referral for 
facility-based treatment was not accepted. this “package” of inter-
ventions, implemented through home visits by community health 
workers (CHWs), resulted in a 34% reduction in neonatal mortality 
rate compared with baseline. In Karachi, pakistan, an open-label trial 
in 434 young infants with possible serious bacterial infection (pSBI) 
whose families refused hospitalization compared 2 study regimens 
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[Im ceftriaxone once daily (OD) and Im gentamicin OD combined 
with oral trimethoprim-sulfamethoxazole twice daily] with reference 
therapy of 7 days of Im procaine penicillin and gentamicin OD in 
primary health-care clinics and found the penicillin and gentamicin 
combination to be the most effective with a 91% success rate.9 Ceftri-
axone had a success rate of 85%. the success rate with trimethoprim-
sulfamethoxazole and gentamicin regimen was 82%, with signifi-
cantly higher death rate associated with this regimen. Investigators 
noted that programmatic implementation of a 7-day injectable peni-
cillin and gentamicin regimen may be hampered by the difficulty of 
giving 2 daily injections to very small infants. In the pakistan study, 
10% of infants receiving penicillin and gentamicin injections with-
drew after the first day, the families refusing all further injections.9 
extensive family counseling was needed for the completion of 7 days 
of therapy with 2 injections daily. In addition, physicians reported 
that procaine penicillin injections were difficult to mix, viscous and 
hard to administer with narrow bore needles.
meta-analyses of use of oral antibiotics for neonatal pneu-
monia management in community settings also suggest an effect 
on overall and pneumonia-specific mortality.10,11 A recent review 
of the impact of case management strategies on mortality among 
newborns with sepsis or pneumonia found 4 trials evaluating oral 
antibiotics for neonatal pneumonia in nonrandomized, concur-
rently controlled designs. A meta-analysis of these studies sug-
gested reductions in all-cause neonatal mortality [relative risk 
0.75; 95% confidence interval (CI): 0.64–0.89; 4 studies] and 
neonatal pneumonia-specific mortality (relative risk 0.58; 95% 
CI: 0.41–0.82; 3 studies).11
A consultation of WHO, Save the Children/Saving newborn 
lives, united States Agency for International Development, Bill and 
melinda Gates Foundation and newborn health experts convened 
to discuss on newborn infection case management guidelines for 
community settings in london in 2007. the group recommended 
future research to evaluate different combination oral and Im antibi-
otic regimens, or injectable to oral “switch” regimens that would be 
feasible in weak health systems for use in first-level facility and home-
based management algorithms, would be acceptable to families and 
show treatment success rates as close as possible to the current stand-
ard regimen of injectable gentamicin and penicillin for 7–10 days.
MATERIALS AND METHODS
Study Design
this is a randomized controlled open-label equivalence trial 
in young infants with clinically diagnosed severe infections (CSI) 
seen at primary health-care clinics in Karachi, pakistan. the trial 
aims to evaluate if (1) Im gentamicin OD and oral amoxicillin twice 
daily for 7 days; and (2) Im penicillin and gentamicin OD for 2 days 
followed by oral amoxicillin twice daily for 5 days are equivalent to 
7 days of Im procaine penicillin and gentamicin (reference therapy). 
We expect that the proportion of babies who fail therapy at or before 
day 8 will be about 10% in each group. the difference in failure rates 
comparing each of the experimental treatments with the reference 
treatment will be calculated along with 95% CIs. An experimental 
treatment will be considered equivalent to the reference treatment if 
the upper bound on the 95% CI is <5%. the secondary objectives 
are to identify clinical predictors of treatment failure and to deter-
mine the proportion of relapses (young infants who were considered 
cured by day 7, but developed any of the signs of suspected severe 
infection by day 14), and compliance with therapy.
Study Setting
the study areas are in low-income settlements in coastal 
Karachi [Rehri Goth, Ibrahim Hyderi, Ali Akbar Shah Goth and 
FIGURE 1. Map of study area in Karachi, Pakistan.
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Bhains (Cattle) colony] and in Bilal Colony located approximately an 
hour’s drive from the Aga Khan university’s (AKu) Stadium Road 
campus in Karachi (Fig. 1). the coastal areas were originally fishing 
villages, but with the rapid expansion of Karachi have acquired a 
peri-urban character, with multiple ethnic groups and mixed live-
lihoods including fishing, cattle farming for diary production and 
small retail businesses serving the local population. Bilal Colony is 
an urban squatter settlement located in an industrial area of Karachi 
where the leather industry is the dominant business activity.
the Department of paediatrics and Child Health, AKu, has 
been maintaining demographic surveillance and running primary care 
clinics in these areas for several years. Household surveillance for 
pregnancy and newborns was established in 2003. the total population 
of the catchment area under surveillance is about 370,000, with a crude 
birth rate of 33 per 1000. Annually, approximately 10,000 pregnancies 
are actively followed at home by locally recruited and trained women 
working as CHWs. At baseline, that is, before the study began, 58% of 
births occurred at home; almost all attended by unskilled attendants; 
the neonatal mortality rate was 35 per 1000 live births.
CHWs refer sick young infants to the primary care clinic 
for management. the primary health clinics (pHCs) are staffed by 
several (at least 2) physicians, 1 female health visitor and CHWs. 
the pHCs provide free health care to children younger than 5 years, 
including medications, and facilitated referral for hospitalization.
Enrollment
A study physician at the pHC examines all young infants 
referred by the CHWs and any brought directly by the family. the 
recruitment procedure is summarized in Figure 2. eligible infants 
with signs of CSI (table 1) meeting the case definition are enrolled 
in the study if caretakers refuse hospitalization despite provision of 
free facilitated transport and medical care costs and provide consent 
to participate in the trial (table 2). the case definition of CSI used 
represents a modification of the 7-sign clinical algorithm for the 
identification of sick young infants needing referral developed by 
WHO in which the pakistan trial site also participated.12 to increase 
the specificity of diagnosis of the possible severe infection, the fast 
respiratory rate sign has been dropped and the higher than normal 
temperature cutoff increased to 38°C instead of 37.5°C. All clinical 
signs are elicited by physicians performing a standardized physical 
examination. Definitions of clinical signs are provided in Appendix 
(Supplemental Digital Content 1, http://links.lww.com/InF/B620). 
Criteria for exclusion from the trial include acceptance of hospitali-
zation, infants with danger signs indicating very severe infection/
Infant brought to community 
primary healthcare clinic
Consent for examination and recording the 
findings for research purpose given by parents
Check Eligibility
No
Refer to non-study physician
Eligible infant
Offer Hospitalization
Consents to 
participate in trial
Enrolled in the trial
Hospitalized 
IM Procaine penicillin 
and gentamicin once a 
day for seven days
IM gentamicin once a day 
and oral amoxicillin twice 
a day for seven days
IM Procaine penicillin and 
gentamicin once a day for two days 
followed by oral amoxicillin twice a 
day for 5 days
Yes
Refused
Accepted
Yes
Infant with illness is identified at home by community health worker
Accepts referral
Self-referred or referred 
by birth attendant 
Manage per illness guidelines
No
Offer out of trial therapy
No
Registration 
FIGURE 2. Trial profile.
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disease, weight <1500 g, hospitalization for illness in the last 2 
weeks, previous inclusion in the study or refusal to provide consent 
to participate (table 2). For families providing consent for blood 
sampling, 1–3 ml of blood is obtained from the infant for culture 
using aseptic precautions and the sample processed in a BACteC 
peds plus blood culture bottle using a BD 9050 automated blood 
culture system (Becton Dickensen, Franklin lakes, nJ). Any bacte-
rial growth is identified using standard microbiologic procedures. 
Families refusing blood sampling are not excluded from participat-
ing in the trial. All enrollment information is recorded on eligi-
bility and enrollment case record forms. For caretakers providing 
consent, a video recording of the clinical presentation is also made.
Randomization and Allocation Concealment
Randomization is performed via computer-generated ran-
dom numbers. A block randomization strategy with individual 
blocks of varying multiples of 3 is used to periodically balance the 
assignment in the 3 study groups. Randomization lists are strati-
fied by site and by age categories 0–6 and 7–59 days to maintain 
similar composition of ages in all 3 study arms. the group assign-
ment for each unique ID is placed in a sealed opaque envelope by a 
study administrative assistant located centrally (at AKu). the study 
assistants are not involved in any clinical care decisions in the field 
sites. these envelopes are maintained in sequential order at each 
study site in batches of 20–30. Different colored envelopes for 0–6 
(white) and 7–59 days (brown) old infants are used to minimize 
the chances of error in opening the wrong envelope. Once a child’s 
family has consented to participate in the study, the study physician 
obtains the treatment assignment by opening the sealed envelope.
Drug Dosages and Administration
Doses were selected to optimize efficacy, safety and feasibil-
ity for eventual programmatic use. the safety and efficacy of once-
daily dosing of gentamicin in newborns are well-established.13 
procaine penicillin is a long-acting penicillin that has been used 
in a dose of 50,000 u/kg for the treatment of congenital syphilis.13 
High-dose amoxicillin of 80–100 mg/kg is currently recommended 
for the management of childhood pneumonia, in areas where pneu-
mococci with reduced sensitivity to penicillin are common.14 the 
medications are provided by the AKu pharmacy and stored at 
room temperature away from direct sunlight at the study clinics. 
Oral amoxicillin once reconstituted is kept refrigerated at the pHC. 
the morning dose is administered by study personnel in the clinic, 
and the evening dose is administered by a CHW at home. Residual 
medication in the study bottle is measured by study supervisors to 
ascertain compliance with oral therapy. Gentamicin injections are 
given by physicians or paramedical staff. the dosage chart of 6 
weight bands is shown in table 3. Because of ethical considerations 
relating to the use of placebo injections in the infants randomized 
to simplified regimens using oral amoxicillin and the need to assess 
differences in compliance with regimens using fewer injections, 
blinding of therapeutic arms was not possible in this study.
Follow-up and Determination of Treatment Failure 
and Relapse
enrolled infants are followed daily at the pHCs for 7 days by 
study physicians who perform a repeat standardized physical exami-
nation to assess clinical signs of treatment failure. the primary out-
come of this trial is treatment failure within 7 days of enrollment. the 
criteria for the determination of treatment failure are listed in table 4.
As this is an unblinded trial, careful attention to determine 
the clinical signs associated with treatment failure has been built into 
study procedures. All infants who are judged to have treatment failure 
by study physicians and a 10% random sample of infants not meeting 
treatment failure criteria are examined by a second physician on-site, 
who is blinded to the findings of the study physician located in a dif-
ferent room. the second physician records his/her findings on a des-
ignated case record form. A study lady health visitor/midwife reviews 
the forms of the study physicians and second physician for agreement. 
If there is agreement regarding treatment failure, the infant is clas-
sified as a treatment failure. If there is disagreement, a supervising 
physician is asked to evaluate the infant. the supervisor’s decision is 
recorded and considered final. If families consent, a video recording 
of the signs of treatment failure is also made. Infants with treatment 
failure are counseled to accept hospitalization. those who still refuse 
referral are managed at the pHCs with ceftriaxone and gentamicin 
injection therapy. Infants whose families refuse to visit the pHC are 
evaluated at home by study physicians to maximize the number of 
infants who are “per protocol.” enrolled infants are also evaluated 
at the pHCs on study days 11 and 14 to determine whether clinical 
TABLE 1. Case Definition of CSI in Young Infants
Presence of 1 or more of the following 5 signs:
• Severe chest in-drawing
• Axillary temperature >38.0°C
• Axillary temperature <35.5°C
• Movement only when stimulated
• Feeding problems (confirmed by observation of feeding or poor suck 
on digital examination)
TABLE 2. Study Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Infant of 0–59 days from catchment area
One or more signs of possible serious bacterial infection
Family refuses hospitalization
Family provides informed consent
Family accepts hospitalization
Very severe infection/disease characterized by presence of any of the following  
danger signs:
–Unconscious
–Convulsions
–Unable to feed
–Apnea
–Unable to cry
–Cyanosis
–Bulging fontanel
–Persistent vomiting (defined as vomiting following 3 attempts to feed the  
baby within half an hour)
Very low birth weight: weight <1500 g
Major congenital malformations or suspected chromosomal abnormalities
Surgical conditions requiring hospital referral
Hospitalization for illness in the last 2 weeks
Previous inclusion in the study
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relapse has occurred. Relapse is defined as death, development of at 
least 1 of the 5 signs of CSI and/or development of any of the 8 danger 
signs after the day 8 assessment (tables 1–3) up to day 14 follow-up.
Determination of Per-protocol Status
Stringent criteria for the determination of per-protocol sta-
tus have been developed, which take into account both adequacy 
and completeness of clinical assessments and adherence to therapy. 
these are presented in table 5.
Sample Size and Data Analysis
table 6 shows the expected power of different sample size 
choices to demonstrate the similarity of 2 treatments (with a simi-
larity margin of 5%) over the entire 7-day time period from rand-
omization and initiation of treatment. It is assumed that the true 
failure rate in arm A (the gold standard) will be 10% over this time 
period and that the true failure rate in the experimental arm will 
be identical (10%) or only slightly worse (11%). A sample size of 
750 children per arm will provide the study with a power of at least 
70% to demonstrate “similarity” of the treatments if the assump-
tions about failure rates are roughly correct.
Statistical analysis will be based on a comparison of treat-
ment failure rates observed in arms B and C compared with the fail-
ure rate in arm A providing injection penicillin and gentamicin for 
7 days. For each comparison, the point estimate of the failure rate 
difference (experimental – gold standard) between the 2 treatment 
arms will be calculated together with a 2-sided 95% CI. the alterna-
tive treatment will be judged to be “of similar effectiveness” to the 
gold standard treatment (A) if the upper bound of the 95% CI lies 
below the allowed “similarity margin” in the table 6. Both intention-
to-treat and modified per-protocol analyses will be reported.
Data Management and Quality Assurance
All completed CRFs are transferred from pHCs to the 
central Data management unit of AKu on a weekly basis. upon 
entry into the log register, forms are stored at secure location under 
the supervision of dedicated data management staff. Access to all 
CRFs is limited to ensure security and confidentiality. the data are 
entered in customized software designed using microsoft Visual 
Basic 6.0 as front-end and microsoft SQl Server 2005 as back-end 
database for storing all the data. the data entry program has built-
in system checks for implausible, inconsistent or missing values. 
to ensure data quality and minimize data entry errors, all CRFs 
TABLE 3. Antibiotic Dosage by Weight
Weight Band (kg) Amount Per Dose Daily Dose Lower Limit (mg or U/kg/d) Upper Limit (mg or U/kg/d)
Gentamicin: desired range 4–5 mg/kg/d in 0–6 days and 5–6.5 mg/kg in 7–59 days (40 mg/mL injection; single daily injection)
1.5–1.9 0.2 mL 8 mg 4.2 5.3
2.0–2.4 0.25 mL 10 mg 4.2 5.0
2.5–2.9 0.3 mL 12 mg 4.1 4.8
3.0–3.9 0.45 18 mg 4.6 6.0
4.0–4.9 0.65 26 mg 5.3 6.5
5.0–5.9 0.8 32 mg 5.4 6.4
Procaine penicillin: desired range 40,000–60,000 U/kg/d (200,000 U/mL injection; single daily injection)
1.5–1.9 0.4 mL 80,000 U 40,201 53,333
2.0–2.4 0.5 mL 100,000 U 40,161 50,000
2.5–2.9 0.7 mL 140,000 U 48,000 56,000
3.0–3.9 0.9 mL 180,000 U 46,000 60,000
4.0–4.9 1.1 mL 220,000 U 45,000 55,000
5.0–5.9 1.4 mL 280,000 U 47,500 56,000
Amoxicillin: desired range 75–100 mg/kg/d (125 mg/5 mL; twice daily orally)
1.5–1.9 3.0 mL bid 150 mg 75.4 100.0
2.0–2.4 4.0 mL bid 200 mg 80.3 100.0
2.5–2.9 5.0 mL bid 250 mg 83.6 100.0
3.0–3.9 6.0 mL bid 300 mg 75.2 100.0
4.0–4.9 8.0 mL bid 400 mg 80.2 100.0
5.0–5.9 10.0 mL bid 500 mg 83.5 100.0
TABLE 4. Definition of Treatment Failure
1. Any time before the day 8 assessment: Death.
2. At or before the day 8 assessment: Clinical deterioration based on the presence of at least 1 of the following 8 danger signs documented by the study 
physician based on physical examination findings: unconscious, convulsions (may also be diagnosed based on convincing history), unable to feed, 
apnea, cyanosis, bulging fontanel, persistent vomiting (defined as vomiting following 3 attempts to feed the baby within half an hour as assessed by 
study physician).
3. At or before the day 8 assessment: Decision by a study physician to change the antibiotic regimen or add another antibiotic for either of the  
following reasons:
a. New-onset infectious comorbidity (ie, severe omphalitis, bone or joint infection or severe skin or soft tissue infection), or
b. Serious nonfatal antibiotic-associated adverse event (ie, severe diarrhea associated with dehydration, Stevens–Johnson syndrome, anaphylaxis or 
acute renal failure).
4. At or before the day 8 assessment: Hospitalization for any reason.
5. On or after day 3: Occurrence of new signs of suspected sepsis (any of the 5 signs). A “new” sign is one that was not present at the time of  
enrollment. Signs are defined in the same manner as for initial eligibility.
6. On day 4, for infants with multiple signs at enrollment: Presence of at least 2 of the signs that were present on enrollment.
7. On day 4, for infants with a single sign on enrollment: Presence of the same sign that was present on enrollment.
8. On or after day 5: Recurrence of at least 1 of the following signs: fever (temperature ≥38°C) hypothermia (temperature ≤35.5°C), severe chest  
in-drawing, lethargy or poor suck on any follow-up visit. Recurrence implies the presence of the sign on enrollment and documented resolution of 
the sign on at least 1 follow-up visit with subsequent reappearance of the same sign on at least 1 follow-up visit on or after day 5.
9. On day 8: Persistence of any of the 5 signs of sepsis that was present on enrollment.
Zaidi et al The Pediatric Infectious Disease Journal • Volume 32, Number 9, Supplement, September 2013
S24  |  www.pidj.com  © 2013 Aga Khan University
are dual entered by 2 different data input operators. A dual check 
report is included in the data entry software that reports the differ-
ences in the 2 entries. Dual check reports are generated and printed 
once the data entry of each batch of CRFs is complete. Conflicting 
entries are verified from the hard copies and the correct ones are 
highlighted on the report. After carrying out these corrections, the 
report is stored for future reference. Once the 2 entries are 100% 
matched, an error checking report is generated to identify any pos-
sible inconsistent or out of range entries, which could not be picked 
up at the time of data entry. the data entry program maintains the 
audit trails of any change made to the entered data at any stage. 
the entered database with the removal of identifying information 
is transferred to the london School of Hygiene and tropical medi-
cine on a quarterly basis for checking and analysis of treatment 
adherence, clinical follow-up, and treatment failure rates. Quarterly 
reports for the 3 arms combined are produced for the trial Steering 
Committee (see below). Quarterly reports, broken down by arm, 
are produced for the trial data safety monitoring board (see below).
Monitoring for Study Quality and Safety
ensuring good clinical practice and a high standard of com-
pliance with study procedures is a priority. For day-to-day monitor-
ing, 2 dedicated clinician supervisors observe the enrollment pro-
cess from screening to enrollment, randomization, to the delivery 
of therapy and archiving of medicine. these supervisors also check 
case files for errors, inconsistencies and missing values. Refresher 
training and clinical sign interpretation standardization exercises 
using video recordings from the field sites are held monthly to 
ensure consistency in evaluating infants for signs of CSI and treat-
ment failure across all the sites.
A trial Steering Committee comprising independent experts 
appointed by the sponsors of this study is charged with study over-
sight. the trial Steering Committee reviews quarterly reports, and 
members make annual visits to the field sites where they spend a 
week in the field observing study procedures. An independent data 
safety monitoring board monitors study results to ensure safety of 
study participants.
Approvals
this study was reviewed and approved by the Research eth-
ics Review Committees of Aga Khan university, london School 
of Hygiene and tropical medicine, and the WHO. the trial has 
been registered at Clinicaltrials.gov before enrolment was initiated 
(nCt01027429).
DISCUSSION
this trial is designed to determine whether simplified anti-
biotic therapy for young infants with CSI is effective and safe 
in first-level facility settings in an environment of high neona-
tal mortality. trials with similar design are also being done in 
Bangladesh and 3 African countries with location-specific adap-
tations. their study designs are reported elsewhere in this sup-
plement.15,16 the results of these trials will provide much-needed 
TABLE 5. Definitions of Per-Protocol Standards
Per-protocol Partially Per-protocol
Adequacy of clinical follow-up Complete: had documented treatment failure and/ 
or clinical follow-up was completed on all 8 days.
Partially complete: Follow-up was completed on  
assessment days 2–4 and on at least one of days  
5–8, and vital status on day 8 was known.
Treatment adherence Adherent: received 100% of doses of scheduled  
antibiotics on all 7 days or by the time of  
treatment failure (TF) if TF occurs.
Partially adherent: not fully adherent, but received 
100% of scheduled antibiotics on the first 3 days  
of therapy or by the time of TF, and at least 50%  
of all scheduled doses of each antibiotic on days  
4–7 or by the time of TF, and has not received  
any nonstudy injectable antibiotic before day 8  
assessment (unless given due to treatment  
failure) or any nonstudy oral antibiotic on days 1–3.
TABLE 6. Power of Different Effective Sample Sizes to Demonstrate the Similarity of 2 Treatments (with a Similarity 
Margin of +5%) Under Different Assumptions About True Similarity of the 2 Treatments (Identical or Difference of 1% 
in True Failure Rates)
True Failure Rate in 
Group A (%)
True Failure Rate in  
Group B or Group C (%)
Number of “Per-protocol”  
Children Per Arm
Allowed Similarity 
Margin (%)
Probability That Study Will Demonstrate 
Similarity of the 2 Treatments Within  
the Allowable Margin (%)
10 10 550 +5 79
10 10 600 +5 82
10 10 650 +5 85
10 10 700 +5 88
10 10 750 +5 90
10 10 800 +5 92
10 10 850 +5 93
10
10
10
11
1500
550
+5
+5
99
58
10 11 600 +5 62
10 11 650 +5 65
10 11 700 +5 68
10 11 750 +5 71
10 11 800 +5 74
10 11 850 +5 77
10 11 1500 +5 95
The Pediatric Infectious Disease Journal • Volume 32, Number 9, Supplement, September 2013 Infants in Pakistan
© 2013 Aga Khan University  www.pidj.com  | S25
information to policy makers on the most appropriate regimen 
to include when scaling up community-based newborn or young 
infant care programs.
Several considerations underlie the design of this trial in 
Karachi and are discussed in detail elsewhere in this supplement.17 
this study was undertaken in primary care clinic settings rather 
than homes to deliver injectable antibiotic therapy to young infants 
with pSBI with a view to address ease of potential programmatic 
uptake in pakistan. Recently, the pakistan government has provided 
funding to revitalize basic health units for curative service deliv-
ery and a combination of early identification of sick young infants 
at home by the government’s lady health workers and referral to 
the nearest basic health unit for the management of those refusing 
referral. this should minimize concerns about indiscriminate gen-
tamicin use, injection safety and antimicrobial resistance.
We have chosen to exclude young infants with very severe 
disease (table 2) because of ethical considerations regarding the use 
of oral medication in these infants when we have the capability of 
giving parenteral therapy, which will limit generalizability of study 
findings. Such infants are either hospitalized or if families refuse 
hospitalization, receive daily Im procaine penicillin and gentamicin 
injections, or oral amoxicillin if injectable therapy is refused. there-
fore, we will have availability of the data and outcome of the entire 
cohort of young infants with CSI whether or not they participated 
in the trial, as well as those with very severe disease, which will be 
reported separately, and will provide additional valuable informa-
tion on the impact of case management for all young infants with 
clinical illness compatible with serious bacterial infections.
the trial will report results for treatment failure outcomes 
for young infants 0–59 days of age. Although we recognize that 
the pathophysiology of early-onset sepsis is distinct from late-onset 
sepsis, and therefore, treatment failure rates with simplified regi-
mens may be different, sample size limitations preclude sufficient 
power to detect differences between these therapies for 0- to 6-day 
and 7- to 59-day-old infants separately. However, because 3 trials 
using similar regimens are currently underway, pooled analyses of 
infants in these age groups may have sufficient power to detect, if 
any, or exclude differences.
the main risk in this trial is therapy failure and potential death 
in young infants with CSI pSBI. From previous experience, we know 
that infants receiving a procaine penicillin- and gentamicin-based 
regimen in our clinic settings experience a case fatality rate of about 
2%, whereas infants whose families refuse any antibiotic therapy 
have a case fatality rate of 20%.9 every effort is being made to pre-
vent adverse outcomes and death among trial participants, including 
home visits in the evening and 24-hour hotline availability to address 
concerns and arrange referrals, if needed. two percent case fatality 
has been set as a benchmark to trigger an additional safety review if 
the observed death rate at 1 week exceeds this figure.
Finally, we believe that the findings from this trial will also 
be of interest to the global pediatric community if we can iden-
tify young infants with CSI who are at low risk of therapy failure 
with outpatient management, potentially preventing many hospital 
admissions.
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